Brian Van Tine, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Apexigen,INC
    Topic:
    Attended a Virtual Advisory Board Meeting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    PTC Therapuetics
    Topic:
    Attended an Advisory Board Meeting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Boehringer Ingelheim
    Topic:
    Attending an Advisory Board Meeting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Agenus
    Topic:
    Attended an Ad Board Meeting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron Pharmaceuticals
    Topic:
    Epithelioid Sarcoma Advisory Board -
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Curis
    Topic:
    VISTA AdBoard
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Polaris
    Topic:
    Nonpaid Board member
    Date added:
    08/11/2023
    Date updated:
    08/11/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond